Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Zobair M. Younossi, Rohit Loomba, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Naga P. Chalasani, Quentin M. Anstee, Kris V. Kowdley, Jacob George, Zachary D.

Survival of children after liver transplantation for hepatocellular carcinoma

Ulrich Baumann, René Adam, Christophe Duvoux, Rafael Mikolajczyk, Vincent Karam, Lorenzo D'Antiga, Christophe Chardot, Ahmet Coker, Michele Colledan, Bo‐Goran Ericzon, Pål Dag Line, Nedim Hadzic, Helena Isoniemi, Jürgen L. Klempnauer, Raymond Reding, Patrick J. McKiernan, Valérie McLin, Andreas Paul, Mauro Salizzoni, Emanuel San Bento Furtado, Stefan Schneeberger, André Karch, for the European Liver and Intestine Transplant Association – 9 December 2017 – Hepatocellular carcinoma (HCC) in childhood differs from adult HCC because it is often associated with inherited liver disease.

Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1‐PRKACA fusion

Rondell P. Graham, Carolin Lackner, Luigi Terracciano, Yessica González‐Cantú, Joseph J. Maleszewski, Patricia T. Greipp, Sanford M. Simon, Michael S. Torbenson – 9 December 2017 – Fibrolamellar carcinomas are characterized by activation of protein kinase A, a kinase composed of catalytic and regulatory subunits. PRKACA encodes a catalytic subunit of protein kinase A, and almost all fibrolamellar carcinomas have a heterozygous 400‐kb deletion that leads to the fusion of DNAJB1 and PRKACA.

Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Zobair M. Younossi, Rohit Loomba, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael R. Charlton, Naga P. Chalasani, Quentin M. Anstee, Kris V. Kowdley, Jacob George, Zachary D.

CD36 deficiency attenuates immune‐mediated hepatitis in mice by modulating the proapoptotic effects of CXC chemokine ligand 10

Che Xu, Chen Zhang, Jie Ji, Chao Wang, Jing Yang, Biao Geng, Ting Zhao, Hong Zhou, Xianmin Mu, Jinshun Pan, Shi Hu, Yuanfang Lv, Xingguo Chen, Hao Wen, Qiang You – 8 December 2017 – The scavenger receptor CD36 recognizes a diverse set of ligands and has been implicated in a wide variety of normal and pathological processes, including lipid metabolism, angiogenesis, atherosclerosis, and phagocytosis. In particular, recent findings have demonstrated its crucial functions in sterile inflammation and tumor metastasis. However, the role of CD36 in immune‐mediated hepatitis remains unclear.

Significance and mechanism of androgen receptor overexpression and androgen receptor/mechanistic target of rapamycin cross‐talk in hepatocellular carcinoma

Hong Zhang, Xiao‐Xing Li, Yang Yang, Yanjie Zhang, Hui‐Yun Wang, X.F. Steven Zheng – 8 December 2017 – Hepatocellular carcinoma (HCC) is a male‐dominant cancer, and androgen receptor (AR) has been linked to the pathogenesis of HCC. However, AR expression and its precise role in HCC remain controversial. Moreover, previous antiandrogen and anti‐AR clinical trials in HCC failed to demonstrate clinical benefits. In this study, we found that AR is overexpressed in the nucleus of approximately 37% of HCC tumors, which is significantly associated with advanced disease stage and poor survival.

Subscribe to